Tech Company Financing Transactions
Oncoceutics Funding Round
Spring Mountain Capital and private investors participated in a Series A capital raise for Oncoceutics. The round closed on 10/7/2015.
Transaction Overview
Company Name
Announced On
10/7/2015
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Spring Mountain Capital (Lead Investor) (Raymond Wong)
Proceeds Purpose
The company will use the proceeds of the financing in conjunction with non-dilutive grant awards, public-private partnerships and academic alliances to continue the development of its lead drug compound, ONC201, a first-in-class, orally-active small molecule that penetrates the blood-brain barrier and exhibits strong anticancer activity in aggressive preclinical models of a number of different types of cancer, including lymphoma and glioblastoma multiforme (GBM).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3675 Market St. 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Overview
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company's leadership team represents a group of drug development executives with unparalleled success in the industry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lee Schalop
VP - Bus. Development
Martin Stogniew
VP - R & D
Joshua Allen
Browse more venture capital transactions:
Prev: 10/7/2015: Canva venture capital transaction
Next: 10/7/2015: BLiNQ Networks venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs